Giuseppe Vergaro

7.4k total citations · 2 hit papers
169 papers, 3.6k citations indexed

About

Giuseppe Vergaro is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Nephrology. According to data from OpenAlex, Giuseppe Vergaro has authored 169 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Cardiology and Cardiovascular Medicine, 84 papers in Molecular Biology and 49 papers in Nephrology. Recurrent topics in Giuseppe Vergaro's work include Amyloidosis: Diagnosis, Treatment, Outcomes (81 papers), Parathyroid Disorders and Treatments (47 papers) and Heart Failure Treatment and Management (37 papers). Giuseppe Vergaro is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (81 papers), Parathyroid Disorders and Treatments (47 papers) and Heart Failure Treatment and Management (37 papers). Giuseppe Vergaro collaborates with scholars based in Italy, United States and United Kingdom. Giuseppe Vergaro's co-authors include Michele Emdin, Claudio Passino, Alberto Aimo, Vincenzo Castiglione, Alberto Giannoni, Andrea Barison, Claudio Rapezzi, Luigi Francesco Saccaro, James L. Januzzi and Antoni Bayés‐Genís and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and International Journal of Molecular Sciences.

In The Last Decade

Giuseppe Vergaro

148 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biomarkers for the diagnosis and management of heart failure

2021 255 citations Vincenzo Castiglione, Alberto Aimo et al. Heart Failure Reviews profile →
RNA-targeting and gene editing therapies for transthyretin amyloidosis

2022 120 citations Alberto Aimo, Vincenzo Castiglione et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giuseppe Vergaro Italy	33	1.9k	1.5k	593	456	416	169	3.6k
Alberto Aimo Italy	34	2.3k 1.2×	1.5k 1.0×	465 0.8×	545 1.2×	387 0.9×	225	4.4k
Tetsuro Shishido Japan	36	1.8k 1.0×	1.3k 0.9×	274 0.5×	251 0.6×	519 1.2×	149	4.0k
Sebastian J. Buss Germany	35	2.6k 1.4×	1.2k 0.8×	326 0.5×	259 0.6×	294 0.7×	142	4.5k
B. Daan Westenbrink Netherlands	31	2.0k 1.1×	899 0.6×	295 0.5×	263 0.6×	637 1.5×	101	3.8k
Takanori Arimoto Japan	35	2.1k 1.2×	779 0.5×	319 0.5×	107 0.2×	530 1.3×	181	3.8k
Alison J. Cox Australia	35	1.1k 0.6×	1.2k 0.8×	882 1.5×	163 0.4×	262 0.6×	71	3.6k
Erik Lipšic Netherlands	24	1.1k 0.6×	589 0.4×	248 0.4×	410 0.9×	234 0.6×	103	2.9k
Jean‐Claude Dussaule France	33	1.0k 0.6×	862 0.6×	609 1.0×	210 0.5×	453 1.1×	89	2.9k
Horng H. Chen United States	42	4.3k 2.3×	893 0.6×	391 0.7×	286 0.6×	323 0.8×	165	5.3k
Nerea Varo Spain	37	1.9k 1.0×	896 0.6×	122 0.2×	423 0.9×	372 0.9×	85	4.3k

Countries citing papers authored by Giuseppe Vergaro

Since Specialization

Citations

This map shows the geographic impact of Giuseppe Vergaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Vergaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Vergaro more than expected).

Fields of papers citing papers by Giuseppe Vergaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuseppe Vergaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Vergaro. The network helps show where Giuseppe Vergaro may publish in the future.

Co-authorship network of co-authors of Giuseppe Vergaro

This figure shows the co-authorship network connecting the top 25 collaborators of Giuseppe Vergaro. A scholar is included among the top collaborators of Giuseppe Vergaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuseppe Vergaro. Giuseppe Vergaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Panichella, Giorgia, Alberto Aimo, Vincenzo Castiglione, Giuseppe Vergaro, & Michele Emdin. (2025). Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift. Cardiac failure review. 11. e15–e15. 1 indexed citations

Mori, Federica, Angela Pucci, Vincenzo Castiglione, et al.. (2025). Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis. International Journal of Molecular Sciences. 26(19). 9511–9511.

Genovesi, Dario, et al.. (2024). PET and Cardiac Amyloidosis. Heart Failure Clinics. 20(3). e11–e21.

Magrì, Damiano, Giovanna Gallo, Antonello Maruotti, et al.. (2024). Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis. Heart. 111(6). 269–277.

Aimo, Alberto, Marco Luigetti, Lidia Ciccone, et al.. (2024). Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease. Molecular Neurobiology. 62(3). 2945–2954. 7 indexed citations

Aimo, Alberto, Chiara Arzilli, Giuseppe Vergaro, et al.. (2024). Disease features and management of cardiomyopathies in women. Heart Failure Reviews. 29(3). 663–674. 1 indexed citations

Tomasoni, Daniela, Giuseppe Vergaro, Vincenzo Castiglione, et al.. (2024). The Mayo ATTR-CM Score Versus Other Diagnostic Scores and Cardiac Biomarkers in Patients with Suspected Cardiac Amyloidosis. European Journal of Heart Failure. 27(12). 2990–2997. 4 indexed citations

Genovesi, Dario, Giuseppe Vergaro, Assuero Giorgetti, et al.. (2024). [18F]‐florbetaben PET/CT is sensitive for cardiac AL amyloidosis. European Journal of Clinical Investigation. 54(10). e14270–e14270. 1 indexed citations

Vergaro, Giuseppe, Francesca Forini, Giuseppina Nicolini, et al.. (2024). Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction. International Journal of Cardiology. 409. 132203–132203. 1 indexed citations

10.

Castiglione, Vincenzo, Francesco Gentile, Nicolò Ghionzoli, et al.. (2023). Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction. Cardiac failure review. 9. e09–e09. 16 indexed citations

11.

Aimo, Alberto, Iacopo Fabiani, Giorgia Panichella, et al.. (2023). Valvular heart disease in patients with cardiac amyloidosis. Heart Failure Reviews. 29(1). 65–77. 14 indexed citations

12.

Banydeen, Rishika, Antoine Deney, Jay H. Ryu, et al.. (2023). Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry. Journal of Clinical Medicine. 12(11). 3684–3684. 2 indexed citations

13.

Emdin, Michele, et al.. (2023). Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. European Heart Journal Supplements. 25(Supplement_B). B79–B84. 22 indexed citations

14.

Aimo, Alberto, Vincenzo Castiglione, Giuseppe Vergaro, et al.. (2023). Cardiovascular toxicity from therapies for light chain amyloidosis. Frontiers in Cardiovascular Medicine. 10. 1212983–1212983. 4 indexed citations

15.

Santarelli, Maria Filomena, Dario Genovesi, Vincenzo Positano, et al.. (2021). Deep-learning-based cardiac amyloidosis classification from early acquired pet images. International journal of cardiac imaging. 37(7). 2327–2335. 23 indexed citations

16.

Emdin, Michele, Federico Perfetto, Alberto Aimo, et al.. (2021). Percorso clinico-assistenziale in rete per la diagnosi e la gestione del paziente con amiloidosi cardiaca. Documento di consenso ANMCO Toscana e SIC Tosco-Umbra. Giornale italiano di cardiologia. 22(8). 621–634.

17.

Pucci, Angela, Alberto Aimo, Veronica Musetti, et al.. (2021). Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. Journal of the American Heart Association. 10(20). e020358–e020358. 69 indexed citations

18.

Girolami, Francesca, Giuseppe Vergaro, Maurizio Pieroni, et al.. (2020). Percorso clinico proposto dall’ANMCO Toscana per la diagnosi genetica delle cardiomiopatie in un sistema assistenziale in rete. Giornale italiano di cardiologia. 21(12). 926–934. 2 indexed citations

19.

Emdin, Michele, Alberto Aimo, Claudio Rapezzi, et al.. (2019). Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal. 40(45). 3699–3706. 111 indexed citations

20.

Aimo, Alberto, Gabriele Buda, Marianna Fontana, et al.. (2018). Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology. 271. 152–160. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact